{
    "SPADE_UN_14295": {
        "Clinical Information": [],
        "Patent Information": [],
        "Sequence Information": {
            "SPADE ID": "SPADE_UN_14295",
            "Peptide Name": "T20v5(T20 [I5L, H6R, Q13R, Q15L, E22A, L26V])",
            "Source": "Synthetic construct(derived from T20)",
            "Family": "Retroviridae",
            "Gene": "Not found",
            "Sequence": "YTSLLRSLIEESRNLQEKNEQALLEVDKWASLWNWF",
            "Sequence Length": 36,
            "UniProt Entry": [
                "http://www.uniprot.org/uniprot/P04578"
            ],
            "Protein Existence": "Not found",
            "Biological Activity": [
                "Antimicrobial",
                "Antiviral"
            ],
            "Target Organism": "[Ref.31228294]HIV-1 N43:inhibition of virus infection in U87 cells(IC50=0.17 µg/ml);HIV-1 JRCSF:inhibition of virus infection in U87 cells(IC50=0.15 µg/ml);HIV-1 94UG103:inhibition of pseudovirus infection in U87 cells(IC50=0.14 µg/ml);HIV-1 92BR020:inhibition of pseudovirus infection in U87 cells(IC50=0.50 µg/ml);HIV-1 IAVI C22:inhibition of pseudovirus infection in U87 cells(IC50=0.29 µg/ml);HIV-1 92HT021:inhibition of pseudovirus infection in U87 cells(IC50=0.13 µg/ml);HIV-1 JRCSF-GIA:inhibition of pseudovirus infection in U87 cells(IC50=5.69 µg/ml).",
            "Hemolytic Activity": "No hemolysis information or data found in the reference(s) presented in this entry",
            "Cytotoxicity": "No cytotoxicity information or data found in the reference(s) presented in this entry",
            "Binding Target": "membrane",
            "Linear/Cyclic": "Linear",
            "N-terminal Modification": "Acetylation",
            "C-terminal Modification": "Amidation",
            "Stereochemistry": "L",
            "Structure Description": "Not found",
            "Formula": "C201H306N52O60",
            "Mass": 4410.89,
            "PI": 4.72,
            "Net Charge": -2,
            "Hydrophobicity": -0.6,
            "Half Life": "Mammalian:2.8 hourYeast:10 minE.coli:2 min",
            "Mechanism of action": "The peptide acts by binding to the heptad repeat 1 (HR1) region of gp41 and preventing the interaction of the HR1 and HR2 domains, which is required for virus–cell fusion.(By similar)",
            "Literature": [
                {
                    "Title": "Optimization of peptidic HIV-1 fusion inhibitor T20 by phage display.",
                    "Pubmed ID": "31228294",
                    "Reference": "Protein Sci. 2019 Aug;28(8)1501-1512.",
                    "Author": "Chen G, Cook JD, Ye W, Lee JE, Sidhu SS.",
                    "URL": "http://www.ncbi.nlm.nih.gov/pubmed/?term=31228294"
                }
            ],
            "Frequent Amino Acids": "LES",
            "Absent Amino Acids": "CGHMOPU",
            "Basic Residues": 4,
            "Acidic Residues": 6,
            "Hydrophobic Residues": 16,
            "Polar Residues": 18,
            "Positive Residues": 4,
            "Negative Residues": 6,
            "Similar Sequences": [
                {
                    "SPADE_ID": "SPADE_UN_10278",
                    "Similarity": 1.0,
                    "Sequence": "DKWASLWNWF"
                },
                {
                    "SPADE_ID": "SPADE_UN_10279",
                    "Similarity": 1.0,
                    "Sequence": "KWASLWNWF"
                },
                {
                    "SPADE_ID": "SPADE_UN_24967",
                    "Similarity": 1.0,
                    "Sequence": "KWASLWNWFNITNWLWYIK"
                }
            ]
        }
    }
}